PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21110923-8 2007 Proliferation induced by ET-1 (1x10-10 mol/L) could also be blocked by the addition of either ethylene diamine tetraacetic acid (EDTA, 0.4mmol/L) or nifedipine (1mumol/L). Nifedipine 149-159 endothelin 1 Homo sapiens 25-38 19171135-7 2009 Endothelin-1-induced increases in intracellular Ca(2+) concentrations were significantly inhibited in Ca(2+)-free solution and by BTP-2, SKF96365, and nifedipine. Nifedipine 151-161 endothelin 1 Homo sapiens 0-12 25863672-13 2015 This effect may be due to the partial inhibition of Endothelin-1 (ET-1) by Nifedipine. Nifedipine 75-85 endothelin 1 Homo sapiens 52-64 25863672-13 2015 This effect may be due to the partial inhibition of Endothelin-1 (ET-1) by Nifedipine. Nifedipine 75-85 endothelin 1 Homo sapiens 66-70 19171135-6 2009 Endothelin-1-induced IL-6 production was markedly attenuated by EGTA and various Ca(2+) channel inhibitors such as 3,5-bis(trifluoromethyl)-1H-pyrazole derivative (BTP-2), 1-[beta-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole hydrochloride (SKF96365), and nifedipine. Nifedipine 272-282 endothelin 1 Homo sapiens 0-12 18294657-9 2008 Chelating extracellular Ca2+ or blocking voltage dependent calcium channels by nifedipine also significantly reduced the mitogenic effect of ET-1 and [Ca2+]i increase in SPC-A1 cells. Nifedipine 79-89 endothelin 1 Homo sapiens 141-145 17351003-5 2007 In contrast, blockade of L-type Ca(2+) channels with nifedipine prevented ET-1 from inducing near-synchronous Ca(2+) transients and resultant action potentials, leaving only asynchronous Ca(2+) transients and local Ca(2+) waves. Nifedipine 53-63 endothelin 1 Homo sapiens 74-78 17178974-0 2007 Chronic treatment with long-acting nifedipine reduces vasoconstriction to endothelin-1 in essential hypertension. Nifedipine 35-45 endothelin 1 Homo sapiens 74-86 17178974-8 2007 After chronic treatment with the nifedipine gastrointestinal therapeutic system, the vasoconstrictor effect induced by both ET-1 and phenylephrine was significantly blunted, whereas the response to acetylcholine was significantly increased and the vasodilation to sodium nitroprusside unchanged. Nifedipine 33-43 endothelin 1 Homo sapiens 124-128 9465842-0 1998 Reversal of endothelin-1-induced ocular hemodynamic effects by low-dose nifedipine in humans. Nifedipine 72-82 endothelin 1 Homo sapiens 12-24 16202925-7 2005 Nifedipine (10(-4) M), a blocker of L-type VGCCs, inhibited ET-1 (EC80)-induced constriction to a similar extent at each oxygen tension (52% to 64% inhibition). Nifedipine 0-10 endothelin 1 Homo sapiens 60-64 16202925-8 2005 In contrast, when arteries were normalized at high stretch, constriction to ET-1 was greater at 38 than at 156 or 15 mm Hg oxygen and nifedipine inhibition of ET-1-induced constriction was greater at 38 and 15 mm Hg than at 156 mm Hg oxygen. Nifedipine 134-144 endothelin 1 Homo sapiens 159-163 16202925-9 2005 CONCLUSIONS: VGCCs and nifedipine-insensitive processes underlie the contractile response of chorionic plate arteries to ET-1 and their relative contribution to vasoconstriction is modulated by oxygen tension when vessels are normalized at high stretch. Nifedipine 23-33 endothelin 1 Homo sapiens 121-125 15055432-5 2004 Nifedipine reversed endothelin-1-induced constriction dose-dependently at 10(-7) M and above. Nifedipine 0-10 endothelin 1 Homo sapiens 20-32 11078432-4 2000 The sustained increase of cytosolic and nuclear Ca2+ by ET-1 in both EEC preparations was completely blocked by the calcium chelator ethylene glycol-bis (beta-aminoethylether)-N,N,N",N"-tetra-acetic acid (EGTA) but was insensitive to the L-type Ca2+ channel blocker, nifedipine. Nifedipine 267-277 endothelin 1 Homo sapiens 56-60 11078432-7 2000 Our results suggest that ET-1 receptors are present in human EECs and that their stimulation induces sustained Ca2+ influx through ET(A)-receptor stimulation of a nifedipine-insensitive Ca2+ channel, probably the R-type Ca2+ channel. Nifedipine 163-173 endothelin 1 Homo sapiens 25-29 10578136-8 1999 Nifedipine (10 microM), an L-type Ca2+ channel blocker, attenuated ET-1 responses by 44%. Nifedipine 0-10 endothelin 1 Homo sapiens 67-71 9465842-9 1998 CONCLUSIONS: These results show that nifedipine does not increase optic nerve head blood flow during baseline conditions but reverses ET-1-induced constriction in ocular vasculature at doses that do not affect systemic hemodynamics. Nifedipine 37-47 endothelin 1 Homo sapiens 134-138 14748381-9 2003 Nifedipine is the calcium channel blocker, which improves endothelial nitric oxide availability, antagonises endothelin 1, restores endothelial permeability and low-density lipoprotein deposition. Nifedipine 0-10 endothelin 1 Homo sapiens 109-121 11815352-7 2002 ET-1 mediated contraction in control and patient arteries was reduced in the presence of (10(-5) M) nifedipine. Nifedipine 100-110 endothelin 1 Homo sapiens 0-4 9049464-0 1997 The effect of nifedipine on serum endothelin-1 levels in essential hypertension. Nifedipine 14-24 endothelin 1 Homo sapiens 34-46 9231815-12 1997 Both enalapril and nifedipine treatment prevented the systemic effects of ET-1 infusion in these subjects. Nifedipine 19-29 endothelin 1 Homo sapiens 74-78 9231815-14 1997 Nifedipine pretreatment attenuated the ET-1-induced fall in renal blood flow (from 1088+/-93 to 907+/-68 mL/min) and increase in renal vascular resistance (from 105+/-9 to 133+/-10 mm Hg x min/L). Nifedipine 0-10 endothelin 1 Homo sapiens 39-43 9231815-17 1997 Both enalapril and nifedipine can prevent the systemic effects of ET-1, but nifedipine seems more effective in attenuating the renal constrictor effects of ET-1. Nifedipine 19-29 endothelin 1 Homo sapiens 66-70 9231815-17 1997 Both enalapril and nifedipine can prevent the systemic effects of ET-1, but nifedipine seems more effective in attenuating the renal constrictor effects of ET-1. Nifedipine 76-86 endothelin 1 Homo sapiens 156-160 7562563-9 1995 During coinfusion of nifedipine, plasma endothelin levels increased to similar values as found during endothelin-1 infusion alone. Nifedipine 21-31 endothelin 1 Homo sapiens 102-114 8606524-8 1995 PreproET-1 mRNA was diminished in the presence of nifedipine and rHuEPO and rHuEPO can increase [Ca2+]i in BPAEC, and this increase may be related to the stimulation of ET-1 synthesis and release. Nifedipine 50-60 endothelin 1 Homo sapiens 6-10 8982507-11 1996 Inhibition of Ca2+ channels by nifedipine (0.1 microM) is accompanied by a significant decrease of the maximal response to ET-1 by 40% in the artery and by 30% in the vein. Nifedipine 31-41 endothelin 1 Homo sapiens 123-127 8622612-3 1996 The augmentative effect of endothelin-1 on CRF-induced ACTH secretion (P < .05) was counteracted by pretreatment with nifedipine. Nifedipine 121-131 endothelin 1 Homo sapiens 27-39 8622612-4 1996 Pretreatment with nifedipine further inhibited (P < .01) the GHRH-induced increase in plasma concentrations of GH (P < .05), which, in keeping with previous data, had already been reduced by IV endothelin-1 alone (P < .05). Nifedipine 18-28 endothelin 1 Homo sapiens 200-212 8606524-6 1995 However, when the cells were treated with rHuEPO and nifedipine, the ET-1 levels were decreased, as compared to levels resulting from treatment with rHuEPO alone (41 +/- 6.1 vs. 85 +/- 7.6 pg/ml, p < 0.001, respectively). Nifedipine 53-63 endothelin 1 Homo sapiens 69-73 7562563-12 1995 Because calcium channel blockers have a preferentially preglomerular effect, this suggests that endothelin-1 maintained vasoconstriction of the efferent arteriole in the kidney during nifedipine. Nifedipine 184-194 endothelin 1 Homo sapiens 96-108 7615016-6 1995 Lacidipine (10(-5) -10(-7) M) and nifedipine (10(-5) M) significantly reduced the contractions and decreased the sensitivity to endothelin-1 as compared to control (P < 0.03). Nifedipine 34-44 endothelin 1 Homo sapiens 128-140 7888288-10 1994 In separate experiments, the concentration-relaxation curves to GTN or nifedipine were established in the IMA rings precontracted with ET-1 (10 nM). Nifedipine 71-81 endothelin 1 Homo sapiens 135-139 7721406-2 1995 We studied whether oral use of the angiotensin-converting enzyme inhibitor enalapril (20 mg BID) or the calcium channel blocker nifedipine (60 mg OD) could attenuate these effects of endothelin-1 (2.5 ng/kg per minute for 90 minutes) in six healthy volunteers. Nifedipine 128-138 endothelin 1 Homo sapiens 183-195 7810625-4 1994 The calcium channel blocker nifedipine inhibited ET-1-stimulated renin release but had no effect on PRL release. Nifedipine 28-38 endothelin 1 Homo sapiens 49-53 7888288-13 1994 Pretreatment with 20 or 200 nM of nifedipine slightly but not significantly, altered the maximum contraction induced by ET-1. Nifedipine 34-44 endothelin 1 Homo sapiens 120-124 7888288-16 1994 In contrast, the nifedipine-induced relaxation was difficult to establish due to unsustained contraction to ET-1. Nifedipine 17-27 endothelin 1 Homo sapiens 108-112 1330178-7 1992 The dihydropyridine Ca2+ channel blocker, nifedipine (10(-8) M), induced a rightward shift in the dose-response curve for ET-1. Nifedipine 42-52 endothelin 1 Homo sapiens 122-126 8156652-5 1994 The results showed that BQ123 and the calcium antagonists nisoldipine, isradipine, nitrendipine and nifedipine fully relaxed IMA precontracted with 3 nmol/L ET-1 with the EC50 values of 7.18 +/- 0.09 (-log mol/L) for BQ123, and 7.68 +/- 0.07, 7.02 +/- 0.12, 6.96 +/- 0.08 and 6.89 +/- 0.09 for the calcium antagonists, respectively. Nifedipine 100-110 endothelin 1 Homo sapiens 157-161 8267041-15 1993 The fetal effects of nifedipine and other calcium-channel blockers deserve specific evaluation in intrauterine growth retardation and other pregnancies complicated by elevated fetal levels of endothelin-1. Nifedipine 21-31 endothelin 1 Homo sapiens 192-204 8401564-8 1993 Preincubation of endothelium-denuded SV segments with nifedipine (1 microM) inhibited the sustained response to ET-1 > or = 10 nM by 50%. Nifedipine 54-64 endothelin 1 Homo sapiens 112-116 1472072-5 1992 Ca2+ channel blockers, Nifedipine, Diltiazem and Verapamil (5 microM), reduced ET-1 chemotaxsis more than 60% (P < 0.001). Nifedipine 23-33 endothelin 1 Homo sapiens 79-83 7967349-7 1994 Pretreatment with the calcium channel blocker nifedipine caused renal vasodilation, which compensated for the renal vasocontriction by endothelin-1 and prevented sodium retention. Nifedipine 46-56 endothelin 1 Homo sapiens 135-147 8207561-8 1994 However, calcium channel blockade by brachial artery infusions of maximally vasodilating doses of either verapamil or nifedipine not only abolished the endothelin-induced vasoconstriction but also unmasked the vasodilator potency of high-dose endothelin-1 infusions. Nifedipine 118-128 endothelin 1 Homo sapiens 243-255 8207561-9 1994 The infusion of lower doses of nifedipine indicated that endothelin-1 induced vasoconstriction was reversed by plasma concentrations estimated to be in the therapeutic range. Nifedipine 31-41 endothelin 1 Homo sapiens 57-69 8185413-5 1993 Cromakalim and nifedipine, both at 3 x 10(-5) M, produced 83.9% and 73.3% of the complete relaxation of the endothelin-1-induced contraction, respectively. Nifedipine 15-25 endothelin 1 Homo sapiens 108-120 1561979-0 1992 Reversal of endothelin-1-induced vasoconstriction by nifedipine in human resistance vessels in vivo in healthy subjects. Nifedipine 53-63 endothelin 1 Homo sapiens 12-24 1561979-1 1992 The influence of blockade of voltage-operated calcium channels by nifedipine on endothelin-1-induced vasoconstriction was investigated in 10 healthy volunteers. Nifedipine 66-76 endothelin 1 Homo sapiens 80-92 1561979-4 1992 Endothelin-1-induced vasoconstriction was reversed by the lowest dose of nifedipine, whereas the higher dosages of nifedipine further increased forearm blood flow to 12.5 +/- 6.4 ml/min/100 ml. Nifedipine 73-83 endothelin 1 Homo sapiens 0-12 1561979-5 1992 The percent increase of forearm blood flow during co-infusion of endothelin-1 and the highest dosage of nifedipine was significantly greater compared with nifedipine alone (1,204 +/- 531% vs 833 +/- 426%, p less than 0.05). Nifedipine 155-165 endothelin 1 Homo sapiens 65-77 2035621-3 1991 Ca(2+)-free medium and nifedipine pretreatment significantly curtailed the sustained phase of response to ET-1. Nifedipine 23-33 endothelin 1 Homo sapiens 106-110 1313765-2 1992 Following administration of nifedipine the rise in plasma concentrations of endothelin-1 during the infusion of the peptide was markedly higher (P less than 0.01) than during control experiments without nifedipine. Nifedipine 28-38 endothelin 1 Homo sapiens 76-88 1313765-2 1992 Following administration of nifedipine the rise in plasma concentrations of endothelin-1 during the infusion of the peptide was markedly higher (P less than 0.01) than during control experiments without nifedipine. Nifedipine 203-213 endothelin 1 Homo sapiens 76-88 1313765-4 1992 However, nifedipine apparently influences the elimination of endothelin-1 from the circulation in healthy men. Nifedipine 9-19 endothelin 1 Homo sapiens 61-73 1725414-6 1991 cAMP accumulation, induced by 100 nM ET-1, was blocked by extracellular Ca2+ chelator EGTA, the intracellular Ca2+ chelator TMB-8, and dihydropyridine Ca(2+)-channel antagonist nifedipine (p less than 0.05), whereas ET-1 inhibition of PGE2 release was unaffected. Nifedipine 177-187 endothelin 1 Homo sapiens 37-41 1846783-6 1991 In contrast, both calcium antagonists converted ET-induced vasoconstriction (e.g., delta forearm vascular resistance to ET 50 ng/min/100 ml forearm tissue, 151 +/- 100% and 164 +/- 92% in verapamil and nifedipine groups, respectively) to vasodilation (-35 +/- 12% and -21 +/- 16%, p less than 0.05). Nifedipine 202-212 endothelin 1 Homo sapiens 48-50 1725313-3 1991 Both the Ca(2+)-free medium and nifedipine pretreatment curtailed the sustained phase of the response to ET-1. Nifedipine 32-42 endothelin 1 Homo sapiens 105-109 1725313-7 1991 In aortic rings, both nifedipine and IAA-94 attenuated ET-1-induced contraction. Nifedipine 22-32 endothelin 1 Homo sapiens 55-59 2185119-8 1990 As shown previously for the human bladder muscle, the response to ET-1 in the renal pelvis was nifedipine (1 microM)-resistant while a consistent fraction of the response was blocked by nifedipine in the human renal artery. Nifedipine 95-105 endothelin 1 Homo sapiens 66-70 35419408-0 2022 Effects of Nifedipine Tablets Combined With Magnesium Sulfate on Blood Coagulation Index, Oxidative Stress, NO and ET-1 Levels in Patients With Pregnancy Hypertension. Nifedipine 11-21 endothelin 1 Homo sapiens 115-119 35419408-1 2022 Objective: To explore the effects of nifedipine tablets combined with magnesium sulfate on blood coagulation indexes, oxidative stress and levels of NO and ET-1 in patients with Pregnancy-induced hypertension syndrome (PIH). Nifedipine 37-47 endothelin 1 Homo sapiens 156-160 35419408-11 2022 Conclusion: Nifedipine tablets combined with magnesium sulfate in the treatment of PIH can improve the blood coagulation function of patients, reduce oxidative stress damage, adjust the serum levels of ET-1 and NO, and improve the clinical efficacy. Nifedipine 12-22 endothelin 1 Homo sapiens 202-206